AR049388A1 - Heterociclos como inhibidores de aldosterona sintasa - Google Patents

Heterociclos como inhibidores de aldosterona sintasa

Info

Publication number
AR049388A1
AR049388A1 ARP050102197A ARP050102197A AR049388A1 AR 049388 A1 AR049388 A1 AR 049388A1 AR P050102197 A ARP050102197 A AR P050102197A AR P050102197 A ARP050102197 A AR P050102197A AR 049388 A1 AR049388 A1 AR 049388A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
aryl
substituted
alkylcarbonyl
Prior art date
Application number
ARP050102197A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR049388A1 publication Critical patent/AR049388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a compuestos heterocíclicos,a un proceso para su preparacion y al uso de estos compuestos como medicamentos, en particular como inhibidores de la aldosterona sintasa. Reivindicacion 1: Compuesto de la formula general (1) W es C o, si Z es un enlace y X es C, es también N; X es C o, si Z es un enlace, es también N; Y es C o, si Z es C, es también N; Z es C o un enlace; R a) es H; o b) es alquilo C1-8, alcoxi C1-8, halogeno o trifluorometilo; R1 a) es cicloalquil C3-8- alquilo C0-4 o heterociclil-alquilo C0-4, donde el radical heterociclilo está al menos parcialmente saturado y los radicales no están sustituidos o están sustituidos con 1-4 alcoxi C1-8, alcoxi C1-8-carbonilo, alquiloC1-8, alquil C0-8-carbonilo, alquilsulfonilo C1-8, aril-alcoxi C0-4-carbonilo, arilo, ciano, halogeno, heterociclilo no saturado, oxo, trifluorometoxi, trifluorometilo, o tri-alquilsililo C1-4; o b), si W es N, es también alquilo C1-8, alquenilo C2-8 o alquinilo C2-8; R2 a) es H; o b) es alquilo C1-8, alquil C0-8-carbonilo, cicloalquil C3-8-alquilo C0-4 o heterociclil-alquilo C0-4, cuyos radicales no están sustituidos o están sustituidos con 1-4 alcoxi C1-8, alcoxi C1-8-carbonilo, alquilo C1-8, alquil C0-8-carbonilo, alquilsulfonilo C1-8, aril-alcoxi C0-4-carbonilo, arilo, ciano, halogeno, heterociclilo no saturado, oxo, trifluorometoxi, trifluorometilo o tri-alquilsililo C1-4; n es 0-2; y su sal, profármaco o compuesto en el cual uno o más átomos son reemplazados por sus isotopos estables no radiactivos, en particular una sal para uso farmacéutico, donde, si W, X, Y y Z son C, R1 no es alquilo C1-8 sustituido con un radical piperazinilo.
ARP050102197A 2004-05-28 2005-05-27 Heterociclos como inhibidores de aldosterona sintasa AR049388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH9162004 2004-05-28

Publications (1)

Publication Number Publication Date
AR049388A1 true AR049388A1 (es) 2006-07-26

Family

ID=35033774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102197A AR049388A1 (es) 2004-05-28 2005-05-27 Heterociclos como inhibidores de aldosterona sintasa

Country Status (10)

Country Link
US (2) US7612088B2 (es)
EP (2) EP2261225A1 (es)
JP (1) JP2008500998A (es)
CN (2) CN1997643A (es)
AR (1) AR049388A1 (es)
BR (1) BRPI0510410A (es)
CA (1) CA2568165A1 (es)
IL (1) IL179405A0 (es)
TW (1) TW200611898A (es)
WO (1) WO2005118557A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568159A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) * 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
EP2029604A2 (en) * 2006-05-26 2009-03-04 Novartis AG Aldosterone synthase and/or 11beta-hydroxylase inhibitors
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
EP2069326B1 (en) * 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
US9216221B2 (en) 2008-11-07 2015-12-22 University Of Sheffield Medicament and method of diagnosis for treating subclinical Cushing's syndrome
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
RU2609200C2 (ru) 2011-07-08 2017-01-30 Новартис Аг Способ лечения атеросклероза у субъектов с высоким уровнем триглицеридов
EP2875286B1 (en) 2012-07-20 2017-05-10 Philips Lighting Holding B.V. Lighting device for obtaining a predetermined light distribution at a target area
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MX367525B (es) 2013-02-14 2019-08-26 Novartis Ag Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
HRP20201701T8 (hr) 2013-09-09 2022-01-07 Peloton Therapeutics, Inc. Aril eteri i njihove uporabe
US9884843B2 (en) 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
EP3268362B1 (en) * 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
US11179377B2 (en) 2017-03-10 2021-11-23 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20220024981A1 (en) 2018-11-27 2022-01-27 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3609596A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB8820730D0 (en) 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
HU222117B1 (hu) * 1992-01-27 2003-04-28 Janssen Pharmaceutica N.V. Pirrolo[1,2-c] imidazolil- és imidazo[1,5-a] piridil-csoporttal szubsztituált 1H-benzimidazol-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
EP1311192A4 (en) * 1999-10-22 2006-03-01 Glaxo Group Ltd -G- (IN VIVO) IMAGING
JP2003171294A (ja) 2001-12-04 2003-06-17 Nof Corp 血栓抑制剤および組成物
ES2270143T3 (es) * 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.

Also Published As

Publication number Publication date
TW200611898A (en) 2006-04-16
BRPI0510410A (pt) 2007-10-23
CN1997643A (zh) 2007-07-11
CA2568165A1 (en) 2005-12-15
WO2005118557A3 (en) 2006-02-23
JP2008500998A (ja) 2008-01-17
WO2005118557A2 (en) 2005-12-15
EP2261225A1 (en) 2010-12-15
US20100029694A1 (en) 2010-02-04
US20070208035A1 (en) 2007-09-06
US7612088B2 (en) 2009-11-03
CN1956987A (zh) 2007-05-02
EP1749006A2 (en) 2007-02-07
IL179405A0 (en) 2007-05-15
US20080318978A2 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR049125A1 (es) Heterociclos biciclicos nitrogenados inhibidores de la aromatasa.
AR056888A1 (es) Derivados de heterociclil imidazol
AR060590A1 (es) Compuestos imidazo
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
NI201000011A (es) Derivados de pirimidina 934.
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR053739A1 (es) Compuestos espiro condensados como inhibidores de la aldosterona sintasa
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
AR065280A1 (es) Agentes antiparasitarios
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR067648A1 (es) Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
GT200500286A (es) Analogos de anilino-pirimidina
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure